2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04390386
(ClinicalTrials.gov)
January 1, 202113/5/2020Controlled Study of IC14 for Treatment of ALSAmyotrophic Lateral Sclerosis Trial: A Randomized, Double-Blind, Placebo-Controlled Study: IC14, a Monoclonal Antibody Against CD14Amyotrophic Lateral SclerosisBiological: IC14;Other: PlaceboImplicit BioscienceNULLWithdrawn18 Years70 YearsAll0Phase 2United States
2NCT04309604
(ClinicalTrials.gov)
October 18, 201912/3/2020IC14 for ALS Patients Expanded AccessIC14 for ALS Patients Expanded AccessAmyotrophic Lateral SclerosisBiological: IC14Implicit BioscienceMassachusetts General HospitalNo longer available18 YearsN/AAllUnited States
3NCT03474263
(ClinicalTrials.gov)
September 1, 20199/3/2018IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients WithAmyotrophic Lateral SclerosisBiological: Biologic: IC14 (monoclonal antibody against human CD14)Implicit BioscienceNULLWithdrawn18 Years80 YearsAll0Phase 2Australia;United States
4NCT03508453
(ClinicalTrials.gov)
August 15, 201916/4/2018IC14 for Treatment of Amyotrophic Lateral SclerosisA Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14 for Treatment of Patients With Rapidly Progressive Motor Neuron DiseaseAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseBiological: IC14;Other: PlaceboImplicit BioscienceNULLWithdrawn18 Years75 YearsAll0Phase 2Australia
5NCT03487263
(ClinicalTrials.gov)
October 1, 20179/3/2018Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone DiseaseA Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone DiseaseMotor Neuron Disease;Amyotrophic Lateral SclerosisBiological: IC14Implicit BioscienceRoyal Brisbane and Women's HospitalCompleted18 Years75 YearsAll10Phase 1Australia